Advanced Melanoma Market Report 2026

The advanced melanoma market size has grown strongly in recent years. It will grow from $4.12 billion in 2025 to $4.5 billion in 2026 at a compound annual growth rate (CAGR) of 9.3%. The growth in the historic period can be attributed to limited treatment options for advanced stages, rising melanoma incidence rates, increasing hospital and oncology center infrastructure, growing awareness of skin cancer, adoption of conventional chemotherapy and biological therapies.

The advanced melanoma market size is expected to see strong growth in the next few years. It will grow to $6.37 billion in 2030 at a compound annual growth rate (CAGR) of 9.1%. The growth in the forecast period can be attributed to advancement in immune checkpoint inhibitors, increasing use of targeted therapies like BRAF and MEK inhibitors, expansion of personalized medicine approaches, growing investment in melanoma research, integration of digital health and patient monitoring solutions. Major trends in the forecast period include rising adoption of immunotherapy and targeted therapies, increasing use of biomarker-based treatment selection, expansion of hospital and oncology center capabilities, growing focus on early detection and diagnostic tools, increasing clinical trials and research on advanced melanoma.

The increasing number of severe sunburn cases is expected to drive the growth of the advanced melanoma market in the coming years. Severe sunburns are intense skin burns caused by excessive exposure to ultraviolet (UV) radiation, leading to redness, pain, swelling, and sometimes blistering. The rise in severe sunburn cases is linked to prolonged UV exposure, insufficient sun protection, increased outdoor activities during peak UV hours, and rising temperatures due to climate change. Repeated or early-age severe sunburns cause DNA damage in skin cells, which can result in genetic mutations that trigger melanoma. For instance, in May 2024, according to Melanoma Focus, a UK-based charity supporting the melanoma community, there were 201 hospital admissions due to sunburn in 2022-23, including 89 children and 25 babies under one year old. Additionally, 66% of UK adults aged 16-65 recalled getting sunburned as children, and 65% experienced severe sunburn with blisters at least once. This figure increased to 77% among those with light, pale, or white skin. Therefore, the growing number of severe sunburn cases is contributing to the expansion of the advanced melanoma market.

Major companies in the advanced melanoma market are focusing on developing innovative products, such as personalized vaccines, to enhance treatment efficacy, overcome resistance mechanisms, and provide tailored treatment options that can improve patient outcomes and prolong survival. A personalized vaccine for advanced melanoma is a cancer therapy designed specifically for an individual patient based on the unique genetic mutations in their tumor. For instance, in April 2023, Merck & Co. Inc., a US-based pharmaceutical company, and Moderna Inc., a US-based biotechnology company, received Priority Medicines (PRIME) designation from the European Medicines Agency (EMA) for their investigational personalized mRNA cancer vaccine, mRNA-4157/V940, when used alongside Merck’s anti-PD-1 therapy, KEYTRUDA (pembrolizumab), for the adjuvant treatment of high-risk stage III/IV melanoma patients following complete resection. The personalized cancer vaccine mRNA-4157/V940 contains a single synthetic mRNA coding for up to 34 neoantigens and is designed and manufactured based on the unique mutational profile of the patient’s tumor.

In December 2023, Pfizer Inc., a US-based pharmaceutical company, acquired Seagen Inc. for $43 billion. Through this acquisition, Pfizer’s oncology pipeline doubled in size, encompassing 60 programs across multiple modalities, and will leverage its expertise in protein engineering and medicinal chemistry to advance Seagen’s antibody-drug conjugate (ADC) technology, unlocking potential novel combinations and next-generation biologics. Seagen Inc. is a US-based biotechnology company actively engaged in researching and developing treatments for advanced melanoma, with a focus on its antibody-drug conjugate (ADC) technology.

Major companies operating in the advanced melanoma market are Pfizer Inc., F Hoffmann-La Roche Ltd, Merck & Co. Inc., Bristol-Myers Squibb, AstraZeneca AG, Novartis AG, Amgen Inc., BioNTech SE, Regeneron Pharmaceuticals, Genentech Inc., Exelixis Inc., Dynavax Technologies, Replimune Group, Immunocore Holdings plc, Xencor Inc., Agenus Inc., Nektar Therapeutics, Iovance Biotherapeutics, Adaptimmune Therapeutics, Immutep Ltd., Lytix Biopharma.

North America was the largest region in the advanced melanoma market in 2025. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the advanced melanoma market report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the advanced melanoma market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

Tariffs have impacted the advanced melanoma market by increasing costs for imported biologics, targeted therapy drugs, and immunotherapy reagents. Therapeutic segments such as immune therapy and targeted therapy are most affected, with north america, europe, and asia-pacific regions facing higher procurement costs. This has led to increased treatment expenses and supply chain delays. On the positive side, tariffs have encouraged local manufacturing of biologics and fostered domestic research and development initiatives, boosting regional capabilities.

The advanced melanoma market research report is one of a series of new reports that provides advanced melanoma market statistics, including advanced melanoma industry global market size, regional shares, competitors with a advanced melanoma market share, detailed advanced melanoma market segments, market trends and opportunities, and any further data you may need to thrive in the advanced melanoma industry. This advanced melanoma market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

Advanced melanoma refers to melanoma skin cancer that has spread from its original site to other areas of the body. It includes stage III, where the cancer has reached nearby lymph nodes, and stage IV, where it has metastasized to distant organs. This stage is more difficult to treat and often requires a combination of therapies, including immunotherapy, targeted therapy, chemotherapy, or radiation.

The main therapeutics for advanced melanoma include chemotherapy, biological therapy, targeted therapy, and immune therapy. Chemotherapy for advanced melanoma involves the use of drugs to destroy or slow the growth of rapidly dividing cancer cells. These therapies are distributed through various channels, such as hospital pharmacies, online pharmacies, and retail pharmacies, and are used by multiple end users, including hospitals, cancer research centers, academic institutes, diagnostic centers, ambulatory surgical centers, and others.

The advanced melanoma market consists of revenues earned by entities by providing services such as diagnosis and staging, surgical excision, immunotherapy administration, targeted therapy management, palliative care and support services. The market value includes the value of related goods sold by the service provider or included within the service offering. The advanced melanoma market also includes sales of pembrolizumab, vemurafenib, trametinib, and personalized cancer vaccines. Values in this market are ‘factory gate’ values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

This product will be delivered within 1-3 business days.